- Data support potential for SAT-3247 in multiple degenerative
muscle diseases
- On track to initiate first-in-human clinical trial mid-2024 for
Duchenne muscular dystrophy
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV:
MSCL) (OTCQB: MSCLF), a public biotech company developing new small
molecule therapeutic approaches to improve the treatment of muscle
diseases and disorders, announced today positive preliminary data
showing SAT-3247 can improve skeletal muscle function in a mouse
model of facioscapulohumeral muscular dystrophy (FSHD).
Frank Gleeson, Cofounder and CEO of Satellos, said, “These data
in FSHD, in combination with our preclinical Duchenne studies,
collectively demonstrate the impact of SAT-3247 on improving muscle
regeneration in degenerative muscle diseases. We look forward to
presenting these data at the MDA Clinical and Scientific Conference
2024 and advancing SAT-3247 into clinical trials for Duchenne
muscular dystrophy mid-year.”
Neil Camarta, Co-Founder and CEO of the FSHD Canada Foundation,
said “I’m very pleased. It’s early days, but these results provide
hope for FSHD patients. I’m looking forward to working with
Satellos to accelerate the development of this promising drug
candidate, because time is muscle!”
FSHD is the third most common muscular dystrophy behind Duchenne
(& Beckers) and myotonic dystrophy. FSHD is an adult onset
muscular dystrophy that results in the progressive destruction of
muscle tissue, owed to the erroneous expression of a gene product
called DUX4. Most treatments in development for FSHD are focused on
trying to block the expression of DUX4.
In research conducted under a grant from the FSHD Canada
Foundation, Satellos tested whether treating with SAT-3247 could
counter the progressive destruction of muscle tissue seen in FSHD.
Satellos demonstrated that treatment with SAT-3247 successfully
improved the phenotype of FSHD mice, which was observed as a
significant impact on improving skeletal muscle function.
Satellos’s SAT-3247 is a small molecule designed to inhibit
AAK1, a protein kinase member of the Notch pathway. The Company
believes AAK1 inhibition, independent of dystrophin, has the
capacity to regulate polarity to restore asymmetric muscle stem
cell division, generate muscle progenitor cells, and enable muscle
regeneration.
About Satellos Bioscience Inc.
Satellos is a publicly traded biotechnology company dedicated to
developing life-improving medicines to treat degenerative muscle
diseases. Satellos has incorporated breakthrough research in muscle
stem cell polarity into a proprietary discovery platform, called
MyoReGenXTM, to identify degenerative muscle diseases where
deficits in this process affect muscle regeneration and are
amenable to therapeutic intervention. With this platform, Satellos
is building a pipeline of novel therapeutics to correct muscle stem
cell polarity and promote the body’s innate muscle repair and
regeneration process. The Company’s lead program is an oral, small
molecule drug candidate in development as a potential
disease-modifying treatment for Duchenne muscular dystrophy.
Satellos is headquartered in Toronto, Ontario. For more
information, visit www.satellos.com.
Notice on Forward-Looking Statements
This press release includes forward-looking information or
forward-looking statements within the meaning of applicable
securities laws regarding Satellos and its business, which may
include, but are not limited to, our ability to initiate clinical
studies in mid-2024, our ability to accelerate development plans,,
statements regarding the anticipated benefits to patients from a
small molecule treatment for Duchenne or other indications; the
general benefits of modulating stem cell polarity by administering
small molecule drugs; its/their prospective impact on Duchenne
patients and muscle regeneration generally; the utility of
regenerating muscle by modulating polarity; adoption of Satellos’
approach by the medical community; and Satellos’ technologies and
drug development plans. All statements that are, or information
which is, not historical facts, including without limitation,
statements regarding future estimates, plans, programs, forecasts,
projections, objectives, assumptions, expectations or beliefs of
future performance, occurrences or developments, are
“forward-looking information or statements.” Often but not always,
forward-looking information or statements can be identified by the
use of words such as “shall”, “intends”, “anticipate”, “believe”,
“plan”, “expect”, “intend”, “estimate”, “anticipate”, “potential”,
“prospective” , “assert” or any variations (including negative or
plural variations) of such words and phrases, or state that certain
actions, events or results “may”, “might”, “can”, “could”, “would”
or “will” be taken, occur, lead to, result in, or, be achieved.
Such statements are based on the current expectations and views of
future events of the management of the Company. They are based on
assumptions and subject to risks and uncertainties. Although
management believes that the assumptions underlying these
statements are reasonable, they may prove to be incorrect. The
forward-looking events and circumstances discussed in this release,
may not occur and could differ materially as a result of known and
unknown risk factors and uncertainties affecting the Company,
including, without limitation, risks relating to the pharmaceutical
and bioscience industry, general market conditions and equity
markets, economic factors and management’s ability to manage and to
operate the business of the Company generally, and those risks
listed in the “Risk Factors” section of Satellos’ prospectus dated
May 9, 2023 and Satellos’ Annual Information Form dated April 27,
2023 (both of which are on Satellos’ profile at www.sedarplus.ca).
Although Satellos has attempted to identify important factors that
could cause actual actions, events or results to differ materially
from those described in forward-looking statements, there may be
other factors that cause actions, events or results to differ from
those anticipated, estimated or intended. Accordingly, readers
should not place undue reliance on any forward-looking statements
or information. No forward- looking statement can be guaranteed.
Except as required by applicable securities laws, forward-looking
statements speak only as of the date on which they are made and
Satellos does not undertake any obligation to publicly update or
revise any forward-looking statement, whether resulting from new
information, future events, or otherwise.
No regulatory authority has approved or disapproved the
content of this press release. Neither the TSX Venture Exchange nor
its Regulatory Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240213841653/en/
Investors: Liz Williams, ir@satellos.com Business Development:
Ryan Mitchell, Ph.D., bd@satellos.com Media: Jessica Yingling,
Ph.D., jessica@litldog.com, +1.858.344.8091
Satellos Bioscience (TSXV:MSCL)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Satellos Bioscience (TSXV:MSCL)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
